Piperazine, a Key Substructure for Antidepressants: Its Role in Developments and Structure-Activity Relationships

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Depression is a leading cause of global disability, posing significant economic and social challenges.
• Existing antidepressant treatments face limitations, including treatment resistance and patient relapse.
• A common structural feature in many antidepressants is the piperazine moiety.

Purpose of the Study:

• To critically analyze the significance of the piperazine moiety in antidepressant development.
• To provide an overview of recent (post-2015) developments in designing and synthesizing piperazine-based antidepressants.
• To discuss structure-activity relationship (SAR) studies and ongoing clinical trials of piperazine-based antidepressants.

Main Methods:

• Literature review of scientific publications from 2015 onwards.
• Analysis of preclinical and clinical data on piperazine-based antidepressant candidates.
• Examination of SAR studies to identify key structural features influencing antidepressant activity.

Main Results:

• Piperazine plays a significant role beyond pharmacokinetics, influencing specific binding conformations of antidepressants.
• Recent research focuses on novel piperazine derivatives with improved efficacy and potency.
• Several piperazine-based compounds are in various phases of human testing for depression.

Conclusions:

• The piperazine scaffold is a vital component in the design of effective antidepressants.
• Understanding the SAR of piperazine-based compounds is crucial for optimizing future drug development.
• Continued research into piperazine derivatives holds promise for addressing unmet needs in depression treatment.